Immutep Receives Constructive Feedback from US FDA on its Clinical Development Program for EFTI in Metastatic Breast Cancer
SYDNEY, AUSTRALIA, March 10, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased...